Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.
作者： Lisa Felden , Carmen Walter , Carlo Angioni , Yannick Schreiber , Nils von Hentig
DOI: 10.1007/S11095-013-1285-Z
关键词:
摘要: Purpose Once daily doses of 100–400 mg lumiracoxib have been proposed to inhibit local prostaglandin synthesis longer than systemic due accumulation in inflamed, acidic tissue. Lower, less toxic doses, however, might still achieve the clinical goal and merit further contemplation.
springer.com
core.ac.uk
sci-hub.se 参考文章(41)
T. Lewis, Y. Zotterman, Vascular reactions of the skin to injury The Journal of Physiology. ,vol. 62, pp. 280- 288 ,(1927) , 10.1113/JPHYSIOL.1927.SP002359
Piet Geusens, Willem Lems, Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis Therapeutics and Clinical Risk Management. ,vol. 4, pp. 337- 344 ,(2008) , 10.2147/TCRM.S1209
Kerstin Malmstrom, Aditi Sapre, Heather Couglin, Nancy G.B Agrawal, Ralph S Mazenko, James R Fricke, Etoricoxib in acute pain associated with dental surgery: A randomized, double-blind, placebo- and active comparator-controlled dose-ranging study Clinical Therapeutics. ,vol. 26, pp. 667- 679 ,(2004) , 10.1016/S0149-2918(04)90067-7
Arthur Okumu, Marie DiMaso, Raimar Löbenberg, Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. European Journal of Pharmaceutics and Biopharmaceutics. ,vol. 72, pp. 91- 98 ,(2009) , 10.1016/J.EJPB.2008.10.019
Chandra S. Chaurasia, Markus Müller, Edward D. Bashaw, Eva Benfeldt, Jan Bolinder, Ross Bullock, Peter M. Bungay, Elizabeth C. M. DeLange, Hartmut Derendorf, William F. Elmquist, Margareta Hammarlund-Udenaes, Christian Joukhadar, Dean L. Kellogg, Craig E. Lunte, Carl Henrik Nordstrom, Hans Rollema, Ronald J. Sawchuk, Belinda W. Y. Cheung, Vinod P. Shah, Lars Stahle, Urban Ungerstedt, Devin F. Welty, Helen Yeo, AAPS‐FDA Workshop White Paper: Microdialysis Principles, Application, and Regulatory Perspectives Pharmaceutical Research. ,vol. 24, pp. 1014- 1025 ,(2007) , 10.1177/0091270006299091
B Hinz, B Renner, O Cheremina, D Besz, O Zolk, K Brune, Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing? Annals of the Rheumatic Diseases. ,vol. 68, pp. 289- 291 ,(2009) , 10.1136/ARD.2008.092536
Ronald Esser, Carol Berry, Zhengming Du, Janet Dawson, Alyson Fox, Roger A Fujimoto, William Haston, Earl F Kimble, Julie Koehler, Jane Peppard, Elizabeth Quadros, Joseph Quintavalla, Karen Toscano, Laszlo Urban, John van Duzer, Xiaoli Zhang, Siyuan Zhou, Paul J Marshall, Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2 British Journal of Pharmacology. ,vol. 144, pp. 538- 550 ,(2005) , 10.1038/SJ.BJP.0706078
Jingjing Zhang, Eric L. Ding, Yiqing Song, Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. ,vol. 296, pp. 1619- 1632 ,(2006) , 10.1001/JAMA.296.13.JRV60015
Chieko Shimura, Takahiro Satoh, Ken Igawa, Kosuke Aritake, Yoshihiro Urade, Masataka Nakamura, Hiroo Yokozeki, Dendritic Cells Express Hematopoietic Prostaglandin D Synthase and Function as a Source of Prostaglandin D2 in the Skin American Journal of Pathology. ,vol. 176, pp. 227- 237 ,(2010) , 10.2353/AJPATH.2010.090111
Stefania Tacconelli, Marta L. Capone, Maria G. Sciulli, Emanuela Ricciotti, Paola Patrignani, The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Current Medical Research and Opinion. ,vol. 18, pp. 503- 511 ,(2002) , 10.1185/030079902125001335